Follow The Filings

LRMR Larimar Therapeutics

Larimar Therapeutics earnings company data as of 4:45 AM ET 11/1

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 4 Nov EPS -0.35 — —
Rev — — —

Insider trades

Open-market buys and sales by LRMR's executives, directors and 10% owners in the last 12 months, from their Form 4s

All LRMR insider trades
  • $25.7M bought by 4 insiders
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Thomas Edward Hamilton Director
    Buy
    $167K 50,000 shares at $3.34 +7.5% to stake
    Traded Jul 6 Filed Jul 8
    ↗
  2. James E Flynn Director, +9 joint filers
    Buy
    $25M 5,000,000 shares at $5.00 +414% to stake
    Traded Feb 27 Filed Mar 2
    ↗
  3. Thomas Edward Hamilton Director
    Buy
    $500K 100,000 shares at $5.00 +18% to stake
    Traded Feb 27 Filed Mar 2
    ↗
  4. Frank E Thomas Director
    Buy
    $25K 5,000 shares at $5.00 +250% to stake
    Traded Feb 27 Filed Mar 2
    ↗

Also filed in the last 12 months, not counted as buying or selling: 5 stock grants.

SEC filings

Recent issuer filings from EDGAR, 24 shown.

Filed Form Detail Links
8-K 5.02 Filing Doc
8-K 2.02,8.01,9.01 Filing Doc
10-Q Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 5.07 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,8.01,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G/A — Filing Doc
DEF 14A Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc
8-K 8.01,9.01 Filing Doc
SCHEDULE 13D/A — Filing Doc
8-K 1.01,9.01 Filing Doc
424B5 Filing Doc
424B5 Filing Doc
8-K 8.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 3.02,5.03,9.01 Filing Doc
8-K 2.02,8.01,9.01 Filing Doc
8-K 3.02,5.03,9.01 Filing Doc
8-K 8.01,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 14 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.